
June 26 (Reuters) - Revive Therapeutics Ltd RVV.CD:
REVIVE THERAPEUTICS NEARS COMPLETION OF KEY NERVE AGENT COUNTERMEASURE STUDY WITH CANADIAN DEPARTMENT OF NATIONAL DEFENCE HIGHLIGHTING SIGNIFICANT STOCKPILING OPPORTUNITY
REVIVE THERAPEUTICS LTD - BUCILLAMINE STUDY TO CONCLUDE BY SEPTEMBER 2025
REVIVE THERAPEUTICS LTD - PLANS TO EXPLORE BUCILLAMINE FOR TBI AND VIRAL INFECTIONS